Septerna Inc.

6.10
-0.19 (-3.02%)
At close: Mar 28, 2025, 3:59 PM
6.10
0.00%
After-hours: Mar 28, 2025, 04:05 PM EDT

Company Description

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.

The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease.

It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes.

Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021.

The company was incorporated in 2019 and is headquartered in South San Francisco, California.

Septerna Inc.
Septerna Inc. logo
Country United States
IPO Date n/a
Industry Biotechnology
Sector Healthcare
Employees 73
CEO Dr. Jeffrey T. Finer M.D., Ph.D.

Contact Details

Address:
250 East Grand Avenue
South San Francisco, California
United States
Website https://septerna.com

Stock Details

Ticker Symbol SEPN
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency n/a
CIK Code 0001984086
CUSIP Number 81734D104
ISIN Number US81734D1046
Employer ID 84-3891440
SIC Code 2834

Key Executives

Name Position
Dr. Jeffrey T. Finer M.D., Ph.D. Co-Founder, Chief Executive Officer, President & Director
Elizabeth P. Bhatt M.B.A., M.S. Chief Operating Officer
Gilbert M. Labrucherie C.F.A., J.D. Chief Financial Officer
Samira Shaikhly Chief People Officer
Dr. Arthur Christopoulos BPHARM, Ph.D. Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board
Dr. Daniel Long DPHIL Senior Vice President of Drug Discovery
Dr. Patrick Sexton Ph.D. Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board
Dr. Robert J. Lefkowitz M.D. Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board
Richard Hansen Ph.D. Vice President of Technology
Uwe Klein Ph.D. Senior Vice President of Biological Sciences

Latest SEC Filings

Date Type Title
Mar 27, 2025 S-8 Filing
Mar 27, 2025 10-K Annual Report
Mar 27, 2025 8-K Current Report
Mar 10, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 03, 2025 8-K Current Report
Feb 27, 2025 4 Filing
Feb 27, 2025 4 Filing
Feb 26, 2025 4 Filing
Feb 24, 2025 4 Filing